Serpin B-9 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Serpin B-9 (SERPINB9; UniProt P50453), a cytoplasmic granzyme B inhibitor expressed in HEK293 cells. Suited for enzymatic inhibition assays, inhibitor screens, and antibody validation.
Expression system
HEK293
Cat. #
REC-SerpinB9

In stock

SKU
REC-SerpinB9
$498.00

Target Overview

Serpin B-9 (gene: SERPINB9; UniProt P50453) is a 376-amino-acid intracellular serine protease inhibitor belonging to the clade B (ovalbumin) branch of the serpin superfamily. Unlike secreted serpins, Serpin B-9 is localised to the cytoplasm, where its primary documented function is the inhibition of granzyme B — the pro-apoptotic serine protease delivered by cytotoxic T lymphocytes and natural killer cells into target cells. By neutralising intracellular granzyme B, Serpin B-9 modulates the granule-exocytosis pathway of cytotoxic killing. This recombinant form is produced in HEK293 mammalian cells, providing human-compatible post-translational processing relevant to the native cytoplasmic environment. The full-length 376-residue sequence (UniProt P50453, isoform 1) is expressed and purified to support in vitro research applications. Researchers use this recombinant protein principally in three contexts. First, in granzyme B inhibition assays: recombinant Serpin B-9 is used as a defined inhibitor to establish dose-response relationships with granzyme B activity against fluorogenic or peptide substrates, providing kinetic constants (Ki, stoichiometry of inhibition) under controlled conditions. Second, in inhibitor-displacement and compound-screening studies, where the Serpin B-9/granzyme B complex serves as a reference system to benchmark small-molecule or biologic probes. Third, as a positive-control or loading standard for antibody validation — researchers using the matched Triple Point Biologics anti-Serpin B-9 antibody (SKU: RP-SerpinB9) can run this recombinant protein alongside cell lysates on Western blot at a defined molecular weight to confirm band identity and assess antibody specificity. The HEK293 expression system is appropriate where researchers require a mammalian-glycosylated, folded intracellular serpin that retains inhibitory activity toward granzyme B in solution-based assays.

Background

Serpin B-9 (SERPINB9) is the principal endogenous cytoplasmic inhibitor of granzyme B, the chymotrypsin-like serine protease that cytotoxic T lymphocytes (CTLs) and NK cells deliver into target cells to initiate caspase-dependent and caspase-independent apoptosis. By forming a stable covalent complex with granzyme B, Serpin B-9 effectively titrates the protease before it can process downstream substrates such as caspase-3, BID, and ICAD, thereby modulating the efficiency of immune-mediated cytotoxicity. In basic immunology research, Serpin B-9 has been studied as a determinant of CTL self-tolerance: its expression in cytotoxic effector cells is thought to protect them from fratricide. This has motivated interest in its role across a variety of immune cell types, including macrophages. Huang et al. (2025, PMID 41160211) demonstrated that Serpin B-9 sustains CIITA protein stability in β-glucan-stimulated macrophages, thereby supporting MHC-II expression and Th1 polarisation — linking Serpin B-9 to antigen-presentation biology beyond its canonical anti-apoptotic role. In tumour immunology, Serpin B-9 has been investigated as a resistance mechanism against immune-mediated killing. Greier et al. (2026, PMID 42277718) examined Granzyme B, HIF-1α, VEGFA, and Serpin B-9 co-expression in immune-stimulated slice cultures of head and neck cancer, characterising the relationship between hypoxic signalling and cytotoxic immune escape at the local tumour level. Separately, Han et al. (2025, PMID 40605985) explored nanoparticle-based strategies to inhibit SerpinB9 in cancer models, using suppression of Serpin B-9 to sensitise cells to ferroptosis-inducing agents. Yang et al. (2025, PMID 40846845) identified SerpinB9 upregulation as a component of immunotherapy resistance in pancreatic cancer, studying spermine metabolism as a means to modulate this axis. Beyond oncology, Serpin B-9 has been characterised in inflammatory contexts. Zhang et al. (2026, PMID 41864017) reported that targeting SERPINB9 pharmacologically promotes apoptosis of IL-1B⁺ macrophages in a periodontitis model, illustrating the protein's role in controlling macrophage survival under inflammatory conditions. These published studies collectively frame Serpin B-9 as a research target at the intersection of cytotoxic immunity, tumour immune evasion, macrophage biology, and inflammatory disease. This recombinant reagent supports the in vitro biochemical and cell-free experiments — inhibition kinetics, protein–protein interaction assays, and antibody validation — that underpin this body of research.

Applications

  • Granzyme B inhibition assay: determination of stoichiometry of inhibition (SI) and inhibitory rate constant (kass) using fluorogenic granzyme B substrates (e.g., Ac-IEPD-AFC)
  • Inhibitor-competition assay: use of the Serpin B-9 / granzyme B complex as a reference system to benchmark small-molecule granzyme B inhibitors in IC50 measurements
  • Surface plasmon resonance (SPR) or biolayer interferometry (BLI): direct binding kinetics of Serpin B-9 to granzyme B or candidate interaction partners
  • Western blot positive control: recombinant protein loaded at defined quantity alongside cell lysates to confirm band identity with anti-Serpin B-9 antibody (SKU: RP-SerpinB9)
  • Antibody validation standard for IHC: spiking or spotting recombinant Serpin B-9 as a specificity control when validating anti-SERPINB9 antibodies in tissue sections
  • Pull-down / co-immunoprecipitation input: use as defined bait to identify novel binding partners or to confirm reported interactions (e.g., CIITA) in cell-free systems
  • ELISA standard curve: use as a calibrated antigen standard for quantitative sandwich ELISA development targeting human SERPINB9 in biological samples

References

  1. Greier MDC et al. Granzyme B, HIF-1α, VEGFA and SerpinB9 in the local tumour immune system of immune-stimulated slice cultures of head and neck cancer. BMC Cancer. 2026. doi: 10.1186/s12885-026-16282-x. PMID: 42277718.
  2. Zhang K et al. Repurposing Azilsartan medoxomil attenuates periodontitis by targeting SERPINB9 to promote apoptosis of IL1B(+) macrophages. Int Immunopharmacol. 2026. doi: 10.1016/j.intimp.2026.116523. PMID: 41864017.
  3. Huang X et al. SerpinB9 sustains CIITA to orchestrate MHC-II expression and Th1 differentiation in β-glucan-induced macrophages. Immunol Res. 2025. doi: 10.1007/s12026-025-09715-5. PMID: 41160211.
  4. Yang H et al. Targeting spermine metabolism to overcome immunotherapy resistance in pancreatic cancer. Nat Commun. 2025. doi: 10.1038/s41467-025-63146-2. PMID: 40846845.
  5. Han R et al. Biomimetic self-assembly nanoparticles inhibit serpinB9 and synergistically enhance COD-induced ferroptosis for cancer therapy. Mater Today Bio. 2025. doi: 10.1016/j.mtbio.2025.101982. PMID: 40605985.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; blood plasma

Frequently Asked Questions

What is the expected molecular weight of recombinant Serpin B-9 on SDS-PAGE and Western blot?

Serpin B-9 (UniProt P50453, isoform 1) has a calculated molecular weight of approximately 42 kDa based on its 376-amino-acid sequence. On reducing SDS-PAGE, the recombinant protein produced in HEK293 cells typically resolves as a single band at ~42–44 kDa. The slight upward shift relative to the calculated mass is common for HEK293-expressed serpins and reflects glycosylation or charge contributions. Purity is >95% by SDS-PAGE. If running a Western blot positive control alongside RP-SerpinB9, expect the band between the 37 and 50 kDa markers.

Is this recombinant Serpin B-9 the full-length protein or a truncated active fragment?

This is the full-length 376-residue sequence of human Serpin B-9, corresponding to UniProt P50453 isoform 1, with no truncations or domain deletions. Unlike secreted serpins, Serpin B-9 lacks a signal peptide, and the full-length cytoplasmic form is the biologically relevant inhibitory species. The reactive centre loop (RCL), which presents the P1–P1' residues critical for granzyme B engagement, is intact. HEK293 expression preserves the native tertiary fold required for the stressed (inhibitory) serpin conformation.

What does recombinant Serpin B-9 cleave, and what is its inhibitory target in vitro?

Serpin B-9 does not itself cleave substrates — it is a serine protease inhibitor whose primary documented target is granzyme B (GZMB), a chymotrypsin-like serine protease with a preference for cleavage after Asp residues. In vitro, recombinant Serpin B-9 forms a stable, covalent SDS-resistant complex with granzyme B via its RCL, effectively titrating granzyme B activity. It does not have documented inhibitory activity against granzyme A, elastase, or thrombin at physiologically relevant concentrations, making it a reasonably selective tool for granzyme B inhibition assays.

How do I set up a granzyme B inhibition assay with recombinant Serpin B-9 — what substrate and buffer conditions should I use?

For granzyme B inhibition assays, the standard fluorogenic substrate is Ac-IEPD-AMC (50–100 µM), which is cleaved efficiently by granzyme B at Asp. Run reactions in 50 mM HEPES pH 7.4, 150 mM NaCl, 0.01% Tween-20 at 37°C. Pre-incubate recombinant Serpin B-9 with a fixed concentration of active granzyme B (typically 2–10 nM) for 15–30 minutes before adding substrate to allow stoichiometric complex formation. Because serpins inhibit via a suicide substrate mechanism, the stoichiometry of inhibition (SI) — not a classical IC50 — is the key parameter to determine; expect SI values near 1.0–2.5 for well-folded preparations.

What starting concentration of recombinant Serpin B-9 should I use for a granzyme B inhibition titration?

Begin with a molar titration series spanning 0.5× to 10× the concentration of your granzyme B stock. If working with 5 nM granzyme B, titrate Serpin B-9 from roughly 2.5 nM to 50 nM. Because the inhibition is stoichiometric rather than kinetic in the conventional sense, complete inhibition is observed when Serpin B-9 reaches approximately 1:1 to 2:1 molar excess over granzyme B. The recombinant is supplied at a defined concentration; dilute into the assay buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, our storage buffer) or the recommended assay buffer without glycerol for activity work.

Can I use recombinant Serpin B-9 as a positive control for Western blot with the RP-SerpinB9 antibody?

Yes — this is a validated use case. Load 20–50 ng of recombinant Serpin B-9 per lane alongside your cell lysate samples. The matched rabbit polyclonal antibody RP-SerpinB9 (/anti-serpin-b9-rabbit-polyclonal-antibody) is raised from the same lab and is guaranteed compatible for Western blot. The recombinant will produce a clean band at ~42–44 kDa, confirming antibody specificity and correct molecular weight assignment in your system. This pairing is particularly useful when validating RP-SerpinB9 in lysates from immune or tumor cell lines where endogenous Serpin B-9 expression is variable.

How much recombinant Serpin B-9 should I load as a Western blot positive control, and what antibody dilution is recommended?

Load 25–50 ng per lane for a strong, clean signal with RP-SerpinB9. At 25 ng you get a band comfortably above background without saturating the signal, which is helpful when running alongside lower-expressing cell lysates. For RP-SerpinB9 antibody dilution on Western blot, refer to the antibody datasheet at /anti-serpin-b9-rabbit-polyclonal-antibody; typical starting dilutions for rabbit polyclonals in this format are 1:500–1:2000. The recombinant and antibody are produced in the same lab (TPB has been making protease/inhibitor antibody pairs since 1994), so lot-to-lot compatibility is consistent.

How should I store and handle recombinant Serpin B-9 to preserve inhibitory activity — can I avoid freeze-thaw cycles?

The protein is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol and shipped on dry ice. Store at -20°C in single-use aliquots; avoid repeated freeze-thaw cycles, which progressively denature the serpin fold and shift the conformational equilibrium toward the latent (inactive) form. If you anticipate using the protein over several days, keep working aliquots at 4°C for up to 48–72 hours. Do not dilute far below 0.1 mg/mL without adding carrier protein (0.1% BSA) to prevent adsorptive loss on tube surfaces. Endotoxin is <0.1 EU/µg by LAL, suitable for cell-based assays.

Validation imagery coming soon

Western blot validation figures for REC-SerpinB9 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →